J 2021

Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases

HELCMAN, Martin and Karel ŠMEJKAL

Basic information

Original name

Biological activity of Cannabis compounds: a modern approach to the therapy of multiple diseases

Authors

HELCMAN, Martin (703 Slovakia, guarantor, belonging to the institution) and Karel ŠMEJKAL (203 Czech Republic, belonging to the institution)

Edition

Phytochemistry reviews, Dordrecht, Springer, 2021, 1568-7767

Other information

Language

English

Type of outcome

Článek v odborném periodiku

Field of Study

30104 Pharmacology and pharmacy

Country of publisher

Netherlands

Confidentiality degree

není předmětem státního či obchodního tajemství

References:

Impact factor

Impact factor: 7.741

RIV identification code

RIV/00216224:14160/21:00124272

Organization unit

Faculty of Pharmacy

UT WoS

000708808100002

Keywords in English

Cannabis; Cannabinoid; Terpenoid; Therapy

Tags

Tags

International impact, Reviewed
Změněno: 23/2/2022 16:15, JUDr. Sabina Krejčiříková

Abstract

V originále

Cannabis spp. are some of the most controversial medicinal plants in the world. They contain great amounts of biologically active secondary metabolites, including the typical phenolic compounds called cannabinoids. Because of their low toxicity and complex biological activities, cannabinoids can be useful in the therapy of various diseases, but adverse psychological effects (of Delta(9)-THC in particular) raise concerns. This review summarizes the current knowledge of selected active C. indica compounds and their therapeutic potential. We summarize the main compounds contained in cannabis, the mechanisms of their effects, and their potential therapeutic applications. Further, we mention some of the clinical tests used to evaluate the efficacy of cannabinoids in therapy.

Links

MUNI/A/1688/2020, interní kód MU
Name: Izolace sekundárních metabolitů s potenciální biologickou aktivitou z rostlinných zdrojů (Acronym: Izolace sekundárních metabolitů)
Investor: Masaryk University